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Although a link between sickle cell disease and resistance to severe malaria is well established, the
biochemical relationship between the two is unknown. Ferreira et al. (2011) show that carriers of the
sickle cell mutation increase expression of the heme oxygenase-1 enzyme, which produces antiox-
idant molecules that may prevent severe disease symptoms.Sickle cell disease is a recessive genetic
disorder caused bymutation of the hemo-
globin gene. In affected individuals, red
blood cells display an abnormal ‘‘sickled’’
morphology and show altered biophysical
properties. The epidemiological relation-
ship between sickle cell disease and
severe malaria, caused by Plasmodium
parasites infecting red blood cells, is well
established (Allison, 1954). Homozygous
individuals, carrying two copies of the
mutated ‘‘sickle’’ haemoglobin allele, the
HbS allele, develop sickle cell disease.
Heterozygotic carriers (having the ‘‘sickle
cell trait’’), on the other hand, are spared
disease symptoms but show significant
resistance to severe malaria syndromes
such as cerebral malaria, a neurological
complication of the infection that can
induce long-term cognitive impairment
and death. Retention of the HbS allele
within the human gene pool, specifically
in those with sub-Saharan African
ancestry, can thus be explained by the
survival benefit it has afforded to hetero-
zygotic carriers living in malaria-endemic
areas. However, the biochemical basis
for resistance to severe malaria in hetero-
zygous individuals has remained elusive.
In this issue of Cell, Ferreira et al. (2011)
provide intriguing in vivo evidence that
HbS heterozygous individuals may be
tolerant to Plasmodium infection due to
upregulation of heme oxygenase-1
(HO-1), an enzyme that normally recycles
the contents of spent red blood cells in
the spleen. In individuals carrying the
HbSallele, heme levels arehigher. Ferreira
et al. suggest that HO-1 converts the free
heme into antioxidant molecules thatmay protect against oxidative damage
caused by severe malaria and may also
prevent a pathological immune response.
This group has previously shown
that HO-1 and a product of its activity,
carbon monoxide (CO), can protect
Plasmodium-infected mice from devel-
oping fatal neurological symptoms, in an
experimental model that displays similari-
ties to human cerebral malaria (Pamplona
et al., 2007). Whereas carbonmonoxide is
toxic at high concentrations, at low levels
it plays important and varied physiological
roles, for example as a neurotransmitter,
vasorelaxant, and perhaps crucially, as
an anti-inflammatory agent. Inflammatory
and cellular immune responses play
pivotal roles in mediating cerebral malaria
in mice (although the roles of these
responses in the pathogenesis of human
cerebral malaria are still unclear).
HO-1 and carbon monoxide have been
shown to substantially reduce neurolog-
ical inflammation, in particular the
accumulation of CD8+ T cells in the brain
(Pamplona et al., 2007).
In this study, theauthorsemploya trans-
genic mouse carrying a human HbS allele
to model carriers of the sickle cell trait.
They find that these mice are resistant to
murine cerebral malaria, whereas control
mice, expressing wild-type human hemo-
globin, are susceptible to the disease.
Based on their previous work (Pamplona
et al., 2007), the authors hypothesized
that HO-1 may play a role in HbS-medi-
ated protection. By knocking out single
alleles of either HO-1 or the transcriptional
regulator nrf2 in mice carrying the HbS
allele, they also show that protectionCellfrom murine cerebral malaria depends
on HO-1, which is in turn controlled by
Nrf2. Finally, carbon monoxide inhalation
protects HO-1 knockout mice carrying
the HbS allele from Plasmodium-induced
neurological disease. These results
demonstrate a critical role for HO-1-
induced carbon monoxide in neuropro-
tection in this disease model. Thus, the
authors clearly show in an in vivo model
of sickle cell trait carriers that protection
from severe malaria depends upon
HO-1, which is elevated in the hematopoi-
etic cells of such individuals.
In murine cerebral malaria, disease
severity is closely linked to the number
of parasites in the whole body, known as
parasite biomass (Amante et al., 2010).
The study by Ferreira et al. now suggests
that HbS, HO-1, and carbon monoxide
protect against cerebral malaria without
affecting parasite biomass, leading the
authors to speculate that HbS renders
the host more tolerant of Plasmodium
parasites. Previous models suggested
that HbS inhibits the adherence of para-
sitized red blood cells to host endothelial
tissues (Cholera et al., 2008), prevents
parasite invasion or growth within red
blood cells (Hood et al., 1996), or triggers
improved immunity (Cabrera et al., 2005).
The model proposed by Ferreira et al. is
conceptually different from the previous
ideas because it describes HbS-medi-
ated tolerance, not a reduction in parasite
numbers or virulence.
But how could sickle hemoglobin
produce a more tolerant host? Previous
studies suggest that, compared to
noncarriers, humans who are either145, April 29, 2011 ª2011 Elsevier Inc. 335
Figure 1. HO-1 Protects against Severe
Malaria
Using a mouse model for cerebral malaria, Ferreira
et al. (2011) suggest a biochemical basis for the link
between sickle cell disease and severe malaria.
The figure shows a molecular pathway that may
explain why carriers of the sickle cell trait, who are
heterozygous for the mutation that causes the
disease (HbS), may havemore resistance to severe
malaria symptoms. Mice harboring the human HbS
allele have elevated levels of free heme in the
blood. Free heme is toxic and can cause oxidative
damage, but its effects are suppressed by the
upregulation of heme oxygenase-1 (HO-1), which
converts heme into the antioxidant molecules
carbon monoxide (CO) and biliverdin and releases
iron to bind to ferritin H chain (FtH). HO-1 expres-
sion is regulated by Nrf2. In individuals with the
sickle cell trait, the elevated levels of carbon
monoxide prior to infection may inhibit pathogenic
CD8+ T cell immune responses and also prevent
oxidative tissue damage during severe malaria.homozygous or heterozygous for the HbS
allele have higher levels of free heme in the
blood (i.e., heme that is not safely con-
tained within the hemoglobin protein)
(Muller-Eberhard et al., 1968). Although
free heme is potentially toxic, due to its
oxidative properties, it is neutralized by
HO-1. HO-1 catalyzes the conversion of
free heme to carbon monoxide and bili-
verdin and releases labile iron (Fe) to
bind to another protein called ferritin H336 Cell 145, April 29, 2011 ª2011 Elsevier Inchain (FtH) (Figure 1). Biliverdin can be
converted to bilirubin, which, along with
FtH and carbon monoxide, protects
against oxidative damage. Thus, individ-
uals carrying the HbS allele may be better
equipped to deal with oxidative stress, but
whether this occurs during cerebral ma-
laria remains to be established, particu-
larly given evidence of reduced oxidative
metabolism in the brain during this
disease. Nevertheless, HO-1 has been
detected in leukocytes in the brains of
malaria patients who died of cerebral
malaria (Medana et al., 2001). Future
work may establish whether HO-1 plays
a tissue-protective role in the brain during
malaria, and whether HO-1 levels are
higher in those who survive cerebral
malaria compared to those who die.
A defining characteristic of the murine
cerebral malaria model is that relatively
low numbers of CD8+ T cells, which are
beneficial in other diseases because
they kill infected cells and tumors, appear
to cause catastrophic neurological
pathology. Ferreira and colleagues show
that the HbS allele, HO-1, and carbon
monoxide all substantially inhibit the
accumulation of CD8+ T cells in the brain.
Therefore, it is likely that HbS protects
mice against cerebral malaria, at least
partially, by inhibiting CD8+ T cell
responses. An important future task will
be to determine the relative importance
of cytoprotection (i.e., protection against
oxidative damage) versus immune-cell
regulation in the protection afforded by
sickle hemoglobin, HO-1, and carbon
monoxide. Moreover, it will be important,
although technically challenging, to
establish whether or not small numbers
of highly pathogenic CD8+ T cells are re-
cruited to the brains of patients suffering
from cerebral malaria.
Finally, there seems to be a fine balance
that determines whether free heme is
protective or pathogenic during malaria.
Whereas modest increases in free heme
may protect individuals with the sickle
cell trait from cerebral malaria by
enhancing HO-1 expression, a morec.substantial elevation in free heme levels
appears to play a pathogenic role by
scavenging nitric oxide. Low levels of ni-
tric oxide have been linked to endothelial
dysfunction in human (Yeo et al., 2007)
and mouse severe malaria.
In summary, Ferreira and colleagues
provide a novel explanation for the
50-year-old conundrum of why HbS
carriers are resistant to severe malaria.
Further elucidation of the biochemical
and immunological mechanisms at play
in HbS carriers could pave the way for
new therapeutic strategies to treat the
many thousands of malaria patients who
die each year from severe malaria compli-
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